Hepatitis B Infection Is Spreading Through Indian Households and Most Carriers Skip Screening

The World Health Organization estimates that India has approximately 40 million people living with chronic hepatitis B infection, roughly 3 to 4 percent of the population. That figure makes India one of the highest-burden countries in the world, sitting alongside sub-Saharan Africa in terms of sheer scale. A 2019 seroprevalence analysis published in the Indian Journal of Medical Research found HBsAg prevalence varying between 1.1 percent in some northern states and 4.4 percent in parts of the northeast, confirming that the burden is not evenly distributed and that geography shapes risk in ways most national campaigns miss.
The virus attacks the liver. In its chronic form, it can progress over years to cirrhosis or hepatocellular carcinoma, liver cancer, without producing symptoms obvious enough to send someone to a doctor. The liver does not have pain receptors the way the stomach does. Damage accumulates quietly.
Hepatitis B is 50 to 100 times more infectious than HIV. It survives on surfaces outside the body for up to seven days. In Indian households where a razor, a nail cutter, or a toothbrush is shared between family members, a common practice, not a careless one, the virus has a direct route from one person to the next.
Mother-to-child transmission during childbirth is the single largest driver of chronic infection globally. A child born to an HBsAg-positive mother who does not receive the hepatitis B vaccine and immunoglobulin within 24 hours of birth has a 70 to 90 percent chance of developing chronic infection. That window is narrow and, in many rural facilities across states like Bihar, Jharkhand, and Odisha, it is routinely missed because birth-dose coverage remains inconsistent.

Unscreened blood and unsterilised equipment at smaller clinics and dental practices add another route. The assumption that infection only comes through sexual contact or intravenous drug use is exactly why so many households carry the virus without knowing it. The actual transmission in most Indian families is mundane: a shared blade, an infected mother, a transfusion that predates mandatory blood screening.
India introduced the hepatitis B vaccine into its Universal Immunisation Programme in 2002 and expanded it nationally by 2011. The three-dose schedule, given at birth, six weeks, and fourteen weeks, is free at government health centres. Coverage has improved substantially, but the birth dose remains the weak link. The National Family Health Survey-5 data shows that only about 45 percent of children in India receive the hepatitis B vaccine within 24 hours of birth, the window that matters most for blocking mother-to-child transmission.

Adults born before 2002 received no routine vaccination. This is the generation now in their thirties, forties, and fifties, the working population, many of whom have never been screened and have no idea whether they are among the 40 million carriers. A single blood test, the HBsAg test, would tell them. Most have never had one.
The HBsAg test is a simple blood test available at any diagnostic lab for a few hundred rupees. A positive result triggers a follow-up panel: HBeAg, HBV DNA viral load, liver function tests, and a fibroscan or ultrasound to assess liver health. None of this is complicated. The barrier is not the test, it is the assumption that because there are no symptoms, there is no problem.

Anyone born before universal vaccination, anyone with a family member who is HBsAg-positive, anyone who has shared personal care items or received blood transfusions before 1992 should be screened. Healthcare workers, dialysis patients, and people with multiple sexual partners are in the high-risk category recognised by both the WHO and India's National Viral Hepatitis Control Programme, launched in 2018 under the Ayushman Bharat umbrella.
Antiviral treatment, tenofovir or entecavir, cannot cure chronic hepatitis B, but it suppresses viral replication effectively enough to prevent cirrhosis and liver cancer in most patients who start treatment early. The liver can stabilise. The damage already done cannot be reversed, but further damage can be stopped. That distinction is what makes early screening matter.
The silence of this infection is not mysterious. It is structural: a virus that causes no pain, in a country where routine screening is not yet a habit, spreading through the kind of ordinary household sharing that nobody thinks twice about. The 40 million figure stays large because the people inside it have no reason to suspect they are there.